Career records & work history
Lawyers & Attorneys
Sandy Simon - Lawyer
ISLN:
921167691
Sandy A Simon, 5512540 12Th Ave NW, Seattle, WA 98177
Sandy Simon Phones & Addresses
12540 12Th Ave NW, Seattle, WA 98177 425-7531997
La Jolla, CA
Bronx, NY
Kiona, WA
Laurelton, NY
Mentions for Sandy A Simon
Publications & IP owners
Us Patents
B-Cell Reduction Using Cd37-Specific And Cd20-Specific Binding Molecules
US Patent:
2007005, Mar 15, 2007
Filed:
Jul 25, 2006
Appl. No.:
11/493132
Inventors:
Laura Grosmaire - Hobart WA, US
Jeffrey Ledbetter - Shoreline WA, US
Peter Thompson - Bellevue WA, US
Sandy Simon - Seattle WA, US
William Brady - Bothell WA, US
Jeffrey Ledbetter - Shoreline WA, US
Peter Thompson - Bellevue WA, US
Sandy Simon - Seattle WA, US
William Brady - Bothell WA, US
Assignee:
TRUBION PHARMACEUTICALS, INC. - Seattle WA
International Classification:
A61K 39/395
US Classification:
424144100
Abstract:
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
B-Cell Reduction Using Cd37-Specific And Cd20-Specific Binding Molecules
US Patent:
2008027, Nov 13, 2008
Filed:
Apr 11, 2008
Appl. No.:
12/101701
Inventors:
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Sandy A. Simon - Seattle WA, US
Peter A. Thompson - Bellevue WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Sandy A. Simon - Seattle WA, US
Peter A. Thompson - Bellevue WA, US
Assignee:
TRUBION PHARMACEUTICALS, INC. - Seattle WA
International Classification:
A61K 39/395
C07K 16/18
C12N 15/11
C12N 15/00
C12N 5/06
C12P 21/04
A61P 37/00
C07K 16/18
C12N 15/11
C12N 15/00
C12N 5/06
C12P 21/04
A61P 37/00
US Classification:
4241331, 4241381, 5303873, 536 2353, 4353201, 435365, 435 691
Abstract:
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
B-Cell Reduction Using Cd37-Specific And Cd20-Specific Binding Molecules
US Patent:
2009021, Aug 27, 2009
Filed:
May 7, 2009
Appl. No.:
12/437507
Inventors:
Laura S. Grosmaire - Hobart WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter A. Thompson - Bellevue WA, US
Sandy A. Simon - Seattle WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter A. Thompson - Bellevue WA, US
Sandy A. Simon - Seattle WA, US
William Brady - Bothell WA, US
Assignee:
Trubion Pharmaceuticals, Inc. - Seattle WA
International Classification:
A61K 39/395
C07K 16/18
C07K 16/18
US Classification:
4241351, 5303873, 4241331
Abstract:
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
Cd37 Immunotherapeutic And Combination With Bifunctional Chemotherapeutic Thereof
US Patent:
2009027, Nov 5, 2009
Filed:
Apr 13, 2009
Appl. No.:
12/422780
Inventors:
Phillip Tan - Lynnwood WA, US
Sandy A. Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter A. Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Sandy A. Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter A. Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Assignee:
Trubion Pharmaceuticals, Inc. - Seattle WA
International Classification:
A61K 39/395
C07K 16/18
C07H 21/04
C12N 15/74
C12N 1/00
A61P 35/00
C07K 16/18
C07H 21/04
C12N 15/74
C12N 1/00
A61P 35/00
US Classification:
4241331, 5303873, 536 2353, 4353201, 435243
Abstract:
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B-cell related autoimmune, inflammatory, or hyperproliferative diseases.
Anti-Cd20 Therapeutic Compositions And Methods
US Patent:
2010033, Dec 30, 2010
Filed:
Jun 12, 2008
Appl. No.:
12/664166
Inventors:
Nitin K. Damle - Upper Saddle River NJ, US
Lioudmila Tchistiakova - Andover MA, US
Kyriaki Dunussi-Joannopoulos - Belmont MA, US
Sandy Alexander Simon - Seattle WA, US
William Brady - Bothell WA, US
Laura Sue Grosmaire - Hobart WA, US
Jeffrey Alan Ledbetter - Shoreline WA, US
Lioudmila Tchistiakova - Andover MA, US
Kyriaki Dunussi-Joannopoulos - Belmont MA, US
Sandy Alexander Simon - Seattle WA, US
William Brady - Bothell WA, US
Laura Sue Grosmaire - Hobart WA, US
Jeffrey Alan Ledbetter - Shoreline WA, US
Assignee:
Wyeth - Madison NJ
Trubion Pharmaceuticals Inc. - Seattle WA
Trubion Pharmaceuticals Inc. - Seattle WA
International Classification:
A61K 39/395
C07K 16/28
C07H 21/00
C12N 15/63
C12N 5/10
C12P 21/02
G01N 33/566
A61P 37/02
A61P 29/00
A61P 25/00
A61P 35/00
C07K 16/28
C07H 21/00
C12N 15/63
C12N 5/10
C12P 21/02
G01N 33/566
A61P 37/02
A61P 29/00
A61P 25/00
A61P 35/00
US Classification:
4241351, 5303873, 4241331, 536 2353, 4353201, 435328, 435 696, 435 724
Abstract:
The present invention provides materials and methods for treatment of diseases involving aberrant B-cell activity, using a CD20-specific binding molecule, in particular, antibodies or antigen binding fragment thereof. The compositions disclosed herein is useful for the treatment and diagnosis of B-cell disorders, such as B-cell malignancies and autoimmune diseases.
Cd37 Immunotherapeutic And Combination With Bifunctional Chemotherapeutic Thereof
US Patent:
2011017, Jul 14, 2011
Filed:
Apr 11, 2009
Appl. No.:
12/678857
Inventors:
Philip Tan - Edmonds WA, US
Sandy Alexander Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter Armstrong Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Sandy Alexander Simon - Seattle WA, US
Charles G. Cerveny - Seattle WA, US
Christy Anne Nilsson - Sammamish WA, US
William Brady - Bothell WA, US
Jeffrey A. Ledbetter - Shoreline WA, US
Peter Armstrong Thompson - Bellevue WA, US
Cecile Morales - Seattle WA, US
Assignee:
TRUBION PHARMACEUTICALS, INC. - Seattle WA
International Classification:
A61K 39/395
C07K 16/00
A61P 35/00
C07K 16/00
A61P 35/00
US Classification:
4241331, 5303871, 4241301
Abstract:
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
Cd3 Immunotherapeutics And Uses Thereof
US Patent:
2013019, Aug 1, 2013
Filed:
Nov 15, 2012
Appl. No.:
13/678128
Inventors:
Philip TAN - Lynnwood WA, US
Sandy Alexander SIMON - Seattle WA, US
Charles G. CERVENY - Seattle WA, US
Christy Anne NILSSON - Sammamish WA, US
William BRADY - Bothell WA, US
Jeffrey A. LEDBETTER - Shoreline WA, US
Peter Armstrong THOMPSON - Bellevue WA, US
Cecile MORALES - Seattle WA, US
Sandy Alexander SIMON - Seattle WA, US
Charles G. CERVENY - Seattle WA, US
Christy Anne NILSSON - Sammamish WA, US
William BRADY - Bothell WA, US
Jeffrey A. LEDBETTER - Shoreline WA, US
Peter Armstrong THOMPSON - Bellevue WA, US
Cecile MORALES - Seattle WA, US
Assignee:
EMERGENT PRODUCT DEVELOPMENT SEATTLE, LLC - Seattle WA
International Classification:
C07K 16/46
US Classification:
4241331, 5303873
Abstract:
The present disclosure provides a humanized anti-CD37 small modular immunopharmaceutical (SMIP) molecule, as well as synergistic combination therapies of CD37-specific binding molecules (such as anti-CD37 SMIP proteins or antibodies) with bifunctional chemotherapeutics (such as bendamustine) that can be administered concurrently or sequentially, for use in treating or preventing B cell related autoimmune, inflammatory, or hyperproliferative diseases.
B-Cell Reduction Using Cd37-Specific And Cd20-Specific Binding Molecules
US Patent:
2013026, Oct 10, 2013
Filed:
Mar 15, 2013
Appl. No.:
13/836377
Inventors:
Jeffrey A. Ledbetter - Shoreline WA, US
Peter Armstrong Thompson - Bellevue WA, US
Sandy Alexander Simon - Seattle WA, US
William Brady - Bothell WA, US
Peter Armstrong Thompson - Bellevue WA, US
Sandy Alexander Simon - Seattle WA, US
William Brady - Bothell WA, US
International Classification:
C07K 16/30
US Classification:
4241331
Abstract:
The present invention generally provides methods for B-cell reduction in an individual using CD37-specific binding molecules. In particular, the invention provides methods for B-cell reduction using CD37-specific binding molecules alone, or a combination of CD37-specific binding molecules and CD20-specific binding molecules, in some instances a synergistic combination. The invention further provides materials and methods for treatment of diseases involving aberrant B-cell activity. In addition, the invention provides humanized CD37-specific binding molecules.
NOTICE: You may not use BackgroundCheck or the information it provides to make decisions about employment, credit, housing or any other purpose that would require Fair Credit Reporting Act (FCRA) compliance. BackgroundCheck is not a Consumer Reporting Agency (CRA) as defined by the FCRA and does not provide consumer reports.